Medical device and regenerative medicine company TBYR Health has earned FDA clearance for its B3 gel system, a bioresorbable gel barrier that protects healing tissue planes and preserves mobility following tendon, ligament and skeletal muscle surgeries.
The gel, which is composed of a naturally derived extracellular matrix, helps to temporarily separate tissues during the bone healing phase, according to a June 9 news release.
It can be used for patients following both open and minimally invasive procedures. Commercial sales of the gel will begin by the end of 2025.
